Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00884286
Other study ID # APL-B-013-02
Secondary ID
Status Completed
Phase Phase 2
First received April 17, 2009
Last updated March 28, 2018
Start date December 2004
Est. completion date June 2010

Study information

Verified date February 2011
Source PharmaMar
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.


Description:

A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma.

Primary

• To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.

Secondary

- To further investigate the safety profile of Aplidin® given as 1-hour weekly IV infusion in this patient population.

- To obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.


Recruitment information / eligibility

Status Completed
Enrollment 67
Est. completion date June 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Written informed consent

- Histologically confirmed aggressive lymphomas,

- Patient requires treatment because NHL relapses

- Measurable disease

- Recovery from any non-hematological toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade < 2 symptomatic peripheral neuropathy is allowed.

- Age > 18 years.

- Performance status (ECOG) < 2

- Adequate renal, hepatic, and bone marrow function (assessed < 14 days before inclusion in the study)

- Left ventricular ejection fraction within normal limits.

Exclusion Criteria:

- Prior therapy with Aplidin®.

- Concomitant therapy with any anti-lymphoproliferative agent

- Acute lymphoblastic leukemia.

- CNS lymphoma.

- HIV-associated lymphoma.

- Prior gene therapy with viral vectors.

- More than three previous lines of systemic biological agents or chemotherapies. Wash-out periods since the end of the precedent therapy less than:

- 6 weeks for nitroso-urea or high dose chemotherapy

- 3 weeks for other chemotherapies or biological agents

- 4 weeks for radiation or radionuclide therapy (6 weeks in case of prior extensive external beam radiation (more than 25% of bone marrow distribution).

- 4 weeks for major prior surgery

- 30 days for any investigational product

- 4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation.

- Pregnant or lactating women.

- Men and women of reproductive potential who are not using effective contraceptive methods

- History of another neoplastic disease. Exceptions: Non-melanoma skin cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no evidence of disease for at least 10 years.

- Known cerebral or leptomeningeal involvement.

- Other relevant diseases or adverse clinical conditions

- Treatment with any investigational product in the 30 days period before inclusion in the study.

- Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol

- Limitation of the patient's ability to comply with the treatment or follow-up protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aplidin®
Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.

Locations

Country Name City State
France Centre Hospitalier Lyon Sud Lyon
France Hôpital Saint- Louis Paris
France Institut Gustave Roussy Villejuif
Italy Istituto di ematologia e oncologia medica "L. e. A. Seragnoli" Bologna
Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano
Italy Ospedaliero Universitaria de Modena Modena
Peru Instituto Nacional de Enfermedades Neoplásicas (INEN) Surquillo Lima
Puerto Rico Hospital Español Auxilio Mutuo de Puerto Rico Inc. San Juan
Spain Hospital Clinico de Barcelona Barcelona
Spain Hospital Morales Meseguer Murcia
Spain Hospital Universitario de Salamanca Salamanca
Switzerland Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni Bellinzona

Sponsors (1)

Lead Sponsor Collaborator
PharmaMar

Countries where clinical trial is conducted

France,  Italy,  Peru,  Puerto Rico,  Spain,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate The primary objective of the study was the exploration of the efficacy of plitidepsin when given as a weekly 1-hour infusion on Days 1, 8 and 15 in 4-week cycles to patients with relapsed or refractory aggressive non-Hodgkin's Lymphoma.
The primary efficacy endpoint was the Objective Response Rate, defined as the combined rate of Complete Response (CR), Unconfirmed Complete Response (CRu) and Partial Response (PR) following the definition of response according to the International Working Group (IWG) criteria for Non-Hodgkin's Lymphoma (NHL).
All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Time to Response Onset Time to response onset was defined as the time from the first day of plitidepsin treatment to the first documentation of response. All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Duration of Response Duration of response was defined as the time from the first documented objective response (CR, CRu or PR) to disease progression or death. Patients who had not progressed or died were to have their duration censored at the date of their last disease assessment. All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Time to Progression Time to progression (TTP) was to be calculated from the first day of plitidepsin treatment to the date of disease progression. All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Time to Subsequent Chemotherapy Time to subsequent therapy was to be calculated from the first infusion of the study drug to the start date of the subsequent therapy. Patients without subsequent therapy were to be censored at their last reported date. All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Progression-free Survival Progression-free survival (PFS) was to be calculated from the date of registration to the date of first objective disease progression or death from any cause. Patients who were lost to follow-up without documentation of progression were to be censored at the last date they were assessed and found progression-free.
A patient receiving a new treatment in the absence of documented progression was to be considered as progressing at the time of re-treatment.
All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Secondary Overall Survival Overall survival (OS) was to be calculated from the date of registration to the date of death from any cause. Patients with no documented death were to be censored at the last date they were known to be alive. All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1